Pluristem Cash Flow Conversion Efficiency

Latest as of March 2022: -0.235x

Pluristem cash flow conversion efficiency. Based on the latest financial reports, Pluristem (PSTI) has a cash flow conversion efficiency ratio of -0.235x as of March 2022. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (ILA-9.42 Million ≈ $-25.26K USD) by net assets (ILA40.14 Million ≈ $107.62K USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.

Cash Flow Conversion Efficiency of Pluristem (2014–2021)

Cash flow conversion efficiency of Pluristem from 2014 to 2021. This chart illustrates how Pluristem's cash flow conversion efficiency has evolved over time, based on yearly financial data. View PSTI stock price for real-time trading data and today's change.

Pluristem Cash Flow Conversion Ratio Explained

Pluristem cash flow conversion ratio divides operating cash flow by net assets, so a higher ratio means more cash generated from each unit of shareholder equity.

Pluristem Competitors by Cash Flow Conversion Efficiency

The table below lists competitors of Pluristem ranked by their cash flow conversion efficiency. Also see Pluristem market capitalisation for the company's overall valuation and market capitalisation.

Company	Cash Flow Conversion Efficiency
Aberdeen Global IF Inc NYSE MKT:FCO	0.021x
Baan Rock Garden Public Company Limited BK:BROCK	0.001x
Sol Strategies Inc. Common Shares NASDAQ:STKE	-0.026x
Legacy Iron Ore Ltd AU:LCY	0.095x
JASTECH Ltd KQ:090470	-0.307x
Carbon Streaming Corp NEO:NETZ	0.003x
L&P Global Berhad KLSE:0268	0.032x
IFirma SA WAR:IFI	0.126x

Annual Cash Flow Conversion Efficiency for Pluristem (2014–2021)

The table below shows the annual cash flow conversion efficiency of Pluristem from 2014 to 2021. Review Pluristem financial flexibility index to assess the company's free cash flow relative to its total liabilities.

Year	Net Assets	Operating Cash Flow	Cash Flow Conversion Efficiency	Change
2021-06-30	ILA57.15 Million ≈ $153.22K	ILA-30.91 Million ≈ $-82.87K	-0.541x	-15.07%
2020-06-30	ILA56.10 Million ≈ $150.40K	ILA-26.37 Million ≈ $-70.69K	-0.470x	+65.18%
2019-06-30	ILA21.82 Million ≈ $58.50K	ILA-29.45 Million ≈ $-78.96K	-1.350x	-79.97%
2018-06-30	ILA28.51 Million ≈ $76.43K	ILA-21.38 Million ≈ $-57.32K	-0.750x	-4.98%
2017-06-30	ILA30.25 Million ≈ $81.10K	ILA-21.61 Million ≈ $-57.94K	-0.714x	-47.17%
2016-06-30	ILA38.16 Million ≈ $102.29K	ILA-18.52 Million ≈ $-49.66K	-0.485x	-36.98%
2015-06-30	ILA58.14 Million ≈ $155.88K	ILA-20.61 Million ≈ $-55.24K	-0.354x	-15.14%
2014-06-30	ILA62.12 Million ≈ $166.55K	ILA-19.12 Million ≈ $-51.26K	-0.308x	--

About Pluristem

TA:PSTI Israel Biotechnology & Medical Research

Market Cap

$34.49 Million

ILA12.86 Billion ILA

Market Cap Rank

#23103 Global

#319 in Israel

Share Price

ILA397.70

Change (1 day)

-4.86%

52-Week Range

ILA281.00 - ILA1497.00

All Time High

ILA72010.00